U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula CH4
Molecular Weight 16.0425
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHANE

SMILES

C

InChI

InChIKey=VNWKTOKETHGBQD-UHFFFAOYSA-N
InChI=1S/CH4/h1H4

HIDE SMILES / InChI

Description

Biologically, methanogens in the colon can use carbon dioxide and hydrogen to produce methane as a by-product. It was previously considered that humans do not utilize methane. However, in a recent study on rodents, results demonstrated that methane could exert anti-inflammatory, anti-oxidant and anti-apoptotic effects. Furthermore, it has bee suggested, that methane-rich saline could be a promising therapeutic agent for clinical treatment of pancreatitis. Methane gas may also be a promising option for the clinical treatment of Acute Lung Injury and Spinal Cord Injury. The exact mechanism underlying the antioxidative, anti-inflammatory, and antiapoptotic activities of methane is not obvious. Different researchers have proposed different hypotheses. Some have hypothesized that methane might accumulate transiently at the interfaces of cell membranes, thereby changing the physicochemical properties or the in-situ functionality of proteins embedded within this environment. Other investigators have suggested that methane could exert effects on membrane channels affecting G-proteins, membrane or receptor-mediated signaling, or acetylcholine-activated ion channel kinetics. It is unknown if mammalian cells contain an oxygenase that is capable of using methane as a substrate, or if the biological effects of methane are caused by the formation of small amounts of the reactive alcohol, methanol, and/or changes in the redox milieu of the cell due to changes in NAD(P)+/NAD(P)H ratio, and whether or not there is a cellular “receptor” for methane. There are also questions remaining around the difference between intraperitoneal vs inhaled administration of methane.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
400.0 nM [Ki]
0.4 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Preventing
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Activity of C021 in a chemotaxis assay was performed using 96-well chemotaxis chambers. The chambers were incubated for 3h at 37°C in a humidified 5% CO2 atmosphere. Human CCR4-expressing cells were suspended and treated with various concentration of C021. The The number of cells migrating to the lowe chambers was quantified using a bioluminescent assay ATP-Lite. C021 inhibited chemotaxis in CCR4-expressing cells with IC50 of 0.14 uM.